Celldex Therapeutics, Inc. $CLDX Shares Purchased by American Century Companies Inc.

American Century Companies Inc. lifted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 4.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 815,560 shares of the biopharmaceutical company’s stock after acquiring an additional 35,575 shares during the period. American Century Companies Inc. owned 1.23% of Celldex Therapeutics worth $21,099,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the period. Millennium Management LLC boosted its position in shares of Celldex Therapeutics by 327.3% during the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after buying an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after buying an additional 14,979 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at approximately $861,000. Finally, Geode Capital Management LLC increased its position in Celldex Therapeutics by 5.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,672,980 shares of the biopharmaceutical company’s stock valued at $34,050,000 after acquiring an additional 83,174 shares during the period.

Analyst Ratings Changes

A number of research analysts have issued reports on CLDX shares. The Goldman Sachs Group boosted their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Barclays upped their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $44.50.

Celldex Therapeutics Price Performance

CLDX opened at $30.73 on Tuesday. The business has a 50 day moving average price of $26.06 and a two-hundred day moving average price of $25.77. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -7.90 and a beta of 1.17. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $31.85.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 41.67%. Equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.